The Brown University Psychopharmacology Update 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.---
The Brown University Psychopharmacology Update,Volume 29, Issue 4, Page 3-4, April 2018. (Source: The Brown University Psychopharmacology Update)
Source: The Brown University Psychopharmacology Update - March 9, 2018 Category: Psychiatry Source Type: research
---
The Brown University Psychopharmacology Update,Volume 29, Issue 4, Page 2-3, April 2018. (Source: The Brown University Psychopharmacology Update)
Source: The Brown University Psychopharmacology Update - March 9, 2018 Category: Psychiatry Source Type: research
---
The Brown University Psychopharmacology Update,Volume 29, Issue 4, Page 1-7, April 2018. (Source: The Brown University Psychopharmacology Update)
Source: The Brown University Psychopharmacology Update - March 9, 2018 Category: Psychiatry Source Type: research
Your Medication Information
(Source: The Brown University Psychopharmacology Update)
Source: The Brown University Psychopharmacology Update - March 9, 2018 Category: Psychiatry Tags: Supplement Source Type: research
Research Roundup
— Comparison of three antipsychotics finds similar metabolic profiles
— Folic acid appears to mitigate risk of autistic traits from AED exposure
— Study finds slightly higher ADHD risk in children whose fathers used SSRIs
— Amantadine decreases aggression, but not anger, in TBI patients
— Sertraline fails to improve symptoms of depression in patients with TBI
— Antidepressant effects on patients with long QT syndrome differ by type (Source: The Brown University Psychopharmacology Update)
Source: The Brown University Psychopharmacology Update - March 9, 2018 Category: Psychiatry Tags: Research Roundup Source Type: research
Cardiac malformation risk slightly higher with exposure to methylphenidate in pregnancy
A nationwide cohort study has found an increased risk of cardiac malformations in infants exposed to methylphenidate during the first trimester of pregnancy, but no increased risk of overall congenital malformations from exposure to either methylphenidate or amphetamine. The study represented the first use of a research collaboration under which findings from the U.S. study were replicated using pregnancy registry data from five countries in the Nordic region. (Source: The Brown University Psychopharmacology Update)
Source: The Brown University Psychopharmacology Update - March 9, 2018 Category: Psychiatry Tags: What's New in Research Source Type: research
Adjunctive cannabidiol shows promise in trial for schizophrenia
A Phase 2 double‐blind, placebo‐controlled trial involving 88 patients with schizophrenia has found that cannabidiol used as adjunctive therapy with an antipsychotic resulted in significant improvement in positive symptoms over placebo. Treating clinicians also were more likely to report patient improvement for participants receiving adjunctive cannabidiol than for patients receiving adjunctive placebo. (Source: The Brown University Psychopharmacology Update)
Source: The Brown University Psychopharmacology Update - March 9, 2018 Category: Psychiatry Tags: What's New in Research Source Type: research
Inflammation and clozapine concentrations
Although clozapine is highly effective in managing patients with treatment‐resistant schizophrenia, it possesses a highly variable pharmacokinetic profile influenced by multiple factors. These variables include altered metabolic status as a result of drug‐drug interactions, as well as patient‐specific factors such as smoking1 and infection.2 The mechanism of infection‐related changes in clozapine pharmacokinetics is thought to be related to release of inflammatory cytokines that act as inhibitors of cytochrome P‐450 enzymes.3,4 Two recent case reports discussed the occurrence of elevated serum clozapine concentra...
Source: The Brown University Psychopharmacology Update - March 9, 2018 Category: Psychiatry Authors: Y. W. Francis Lam Tags: Drug ‐Drug Interactions Source Type: research
Varenicline reduces heavy drinking, smoking in men with both risk behaviors
Among a group of patients with alcohol use disorders who were seeking alcohol treatment, varenicline significantly reduced heavy drinking and comorbid smoking in men but not in women, a placebo‐controlled study involving 131 patients found. The gender difference could be attributed in part to lower tolerability of varenicline among women, who reduced or discontinued doses of varenicline in greater numbers than men, the researchers reported. Study results were published online Dec. 20, 2017 in JAMA Psychiatry. (Source: The Brown University Psychopharmacology Update)
Source: The Brown University Psychopharmacology Update - March 9, 2018 Category: Psychiatry Tags: Addiction Treatment Source Type: research
Treatment initiation cited in study comparing extended ‐release naltrexone, buprenorphine
A 24‐week open‐label trial has found that for patients with an opioid use disorder who could be successfully inducted to treatment, injectable extended‐release naltrexone (XR‐NTX) and buprenorphine‐naloxone (BUP‐NX) showed similar outcomes on measures of relapse and abstinence. The challenge of initiating patients on XR‐NTX, which requires that they be completely opioid‐free before starting on the medication, did result in poorer overall outcomes among the full cohort of patients randomized to XR‐NTX, however. Results were published online Nov. 14, 2017, in The Lancet. (Source: The Brown University Psychopharmacology Update)
Source: The Brown University Psychopharmacology Update - February 9, 2018 Category: Psychiatry Tags: Addiction Treatment Source Type: research
Your Medication Information
(Source: The Brown University Psychopharmacology Update)
Source: The Brown University Psychopharmacology Update - February 9, 2018 Category: Psychiatry Tags: Supplement Source Type: research
From the FDA
Approvals (Source: The Brown University Psychopharmacology Update)
Source: The Brown University Psychopharmacology Update - February 9, 2018 Category: Psychiatry Tags: From the FDA Source Type: research
Long ‐term SSRI treatment may delay progression to Alzheimer's disease
(Source: The Brown University Psychopharmacology Update)
Source: The Brown University Psychopharmacology Update - February 9, 2018 Category: Psychiatry Tags: Research Roundup Source Type: research
Why don't SSRIs work in the medical subspecialty clinic?
During a recent supervision session with a resident, the question arose as to whether the diazepam being given to one of his clinic patients with chronic renal insufficiency should be replaced by a benzodiazepine that was either shorter‐acting or without active metabolites (the answer: probably unnecessary, since most of diazepam's metabolism is hepatic). Quite by coincidence, results of the Chronic Kidney Disease Antidepressant Sertraline Trial (CAST) had just been published by Hedayati et al., allowing our supervision discussion to meander onto a related, and probably more important, topic: What is the best way to trea...
Source: The Brown University Psychopharmacology Update - February 9, 2018 Category: Psychiatry Authors: Lawrence H. Price Tags: Editor's Commentary Source Type: research
Ketamine reduces suicidal ideation in trial with midazolam control
A single infusion of ketamine resulted in a greater reduction in suicidal thoughts in comparison with midazolam among patients with depression, with clinical improvement sustained for up to six weeks, a new study has found. Side effects from ketamine were mild to moderate and usually lasted no more than a few hours after infusion. (Source: The Brown University Psychopharmacology Update)
Source: The Brown University Psychopharmacology Update - February 9, 2018 Category: Psychiatry Tags: What's New in Research Source Type: research
